Your browser doesn't support javascript.
loading
Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor-positive Prostate and Breast Cancers.
Tien, Amy H; Sadar, Marianne D.
Affiliation
  • Tien AH; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
  • Sadar MD; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada. msadar@bcgsc.ca.
Mol Cancer Ther ; 21(2): 294-309, 2022 02.
Article in En | MEDLINE | ID: mdl-34815359
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Prostatic Neoplasms / Pyridines / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptors, Androgen / Cyclin-Dependent Kinase 4 / Cyclin-Dependent Kinase 6 Limits: Animals / Female / Humans / Male Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2022 Document type: Article Affiliation country: Canada Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Prostatic Neoplasms / Pyridines / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptors, Androgen / Cyclin-Dependent Kinase 4 / Cyclin-Dependent Kinase 6 Limits: Animals / Female / Humans / Male Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2022 Document type: Article Affiliation country: Canada Country of publication: United States